Please enjoy this Special Edition episode of the Threat Vector podcast with an update on our previous Muddled Libra coverage.

Muddled Libra is back and more dangerous than ever. In this episode of Threat Vector, David Moulton speaks with Sam Rubin and Kristopher Russo from Unit 42 about the resurgence of the threat group also known as Scattered Spider. They break down the group’s shift to destructive extortion, modular attack teams, and cloud-first tactics. Discover why traditional defenses fail, how attackers now exploit trusted tools, and what forward-leaning security leaders are doing to stay ahead. With real-world case studies, strategic advice, and insights from the front lines, this episode helps defenders understand today’s threat landscape and what’s coming next.

Join the conversation on our social media channels:

Website: ⁠⁠⁠⁠https://www.paloaltonetworks.com/
Threat Research: ⁠⁠⁠⁠https://unit42.paloaltonetworks.com/⁠⁠⁠⁠
Facebook: ⁠⁠⁠⁠https://www.facebook.com/LifeatPaloAltoNetworks/⁠⁠⁠⁠
LinkedIn: ⁠⁠⁠⁠https://www.linkedin.com/company/unit42/⁠⁠⁠⁠
YouTube: @paloaltonetworks
Twitter: ⁠⁠⁠⁠https://twitter.com/PaloAltoNtwks⁠⁠⁠⁠

About Threat Vector

Threat Vector by Palo Alto Networks is your premier podcast for security thought leadership. Join us as we explore pressing cybersecurity threats, robust protection strategies, and the latest industry trends.

The podcast features in-depth discussions with industry leaders, Palo Alto Networks experts, and customers, providing crucial insights for security decision-makers.

Whether you're looking to stay ahead of the curve with innovative solutions or understand the evolving cybersecurity landscape, Threat Vector equips you with the knowledge needed to safeguard your organization.

Palo Alto Networks

Palo Alto Networks enables your team to prevent successful cyberattacks with an automated approach that delivers consistent security across the cloud, network, and mobile. ⁠http://paloaltonetworks.com

NEJM Interview: Dr. Anthony Fauci on potential strategies for conducting clinical trials of Zika virus vaccines.